Update and watching for Responce!
$Citius Pharmaceuticals(CTXR.US$ Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission! This is a resubmit from the CRL received from the FDA in JULY 2023! Thinking this time should be GTG? ![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Kevin Matte : nice this one
TrytosaveabitOP Kevin Matte: Yup, got to be in total agreement with you on that! This time there shouldn’t be a issue with the FDA? They supposedly took care of the issue for the CRL back in July? So yup, got high hopes for this one! GL and big profits to ya
Kevin Matte : I'm going to look at this in detail, and perhaps consider this action for my next purchases next week ^^ thanks for the tip!
TrytosaveabitOP Kevin Matte: You’re welcome GL